MAFLD、NAFLD与慢性肾脏病的研究进展

肝脏 ›› 2023, Vol. 28 ›› Issue (10): 1252-1256.

MAFLD、NAFLD与慢性肾脏病的研究进展

冯巩, 李雪萍, 寇喆, 宋娟娟, 贺娜, 范立萍, 弥曼

710021 陕西西安医学院全科医学研究所(冯巩,范立萍,弥曼),临床医学院(李雪萍),公共卫生学院(寇喆,宋娟娟);710061 西安交通大学第一附属医院(冯巩);710077 西安医学院第一附属医院消化内科(贺娜)

收稿日期:2023-01-05 出版日期:2023-10-31 发布日期:2023-12-06
通讯作者: 弥曼, Email:853002274@qq.com
基金资助:
西安医学院2021年校级科研项目(2021QN20);2020陕西省教育厅课题(20JK0343)

Received:2023-01-05 Online:2023-10-31 Published:2023-12-06

摘要/Abstract

摘要： 越来越多的证据表明,非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)不仅是全球范围内临床最常见的慢性肝病,且与慢性肾脏病(chronic kidney disease,CKD)的发病风险增加独立相关。2020年国际专家小组建议将NAFLD更名为代谢相关脂肪性肝病(metabolically related fatty liver disease,MAFLD),新的更名必然需要更多的真实世界研究证据予以评估。由于MAFLD和NAFLD的诊断标准不同,所以二者与CKD的关系必然也存在差异。本文主要就NAFLD/MAFLD与CKD患病的风险分析、NAFLD/MAFLD与CKD的关联机制、MAFLD/NAFLD在筛查CKD方面的差异性进行论述,并强调在临床实践中需要以多学科协作和以人为中心的模式来管理MAFLD/NAFLD合并CKD的患者。

冯巩, 李雪萍, 寇喆, 宋娟娟, 贺娜, 范立萍, 弥曼. MAFLD、NAFLD与慢性肾脏病的研究进展[J]. 肝脏, 2023, 28(10): 1252-1256.

参考文献

[1] Crews DC, Bello AK, Saadi G, et al. Burden, access, and disparities in kidney disease. Am J Nephrol, 2019, 49(3):254-262.
[2] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol, 2019, 71(1):212-221.
[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol, 2020, 73(1):202-209.
[4] Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet, 2021, 398(10302):786-802.
[5] Tao Z, Li Y, Cheng B, et al. Influence of nonalcoholic fatty liver disease on the occurrence and severity of chronic kidney disease. J Clin Transl Hepatol, 2022, 10(1):164-173.
[6] Mantovani A, Petracca G, Beatrice G, et al.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 2022, 71(1):156-162.
[7] Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism, 2018, 79: 64-76.
[8] Younossi ZM. Non-alcoholic fatty liver disease-a global public health perspective. J Hepatol, 2019, 70(3): 531-544.
[9] Yilmaz Y, Alahdab YO, Yonal O, et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism, 2010, 59(9): 1327-1330.
[10] Önnerhag K, Dreja K, Nilsson PM, et al. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. Clin Res Hepatol Gastroenterol, 2019, 43(5): 542-550.
[11] Hashimoto Y, Hamaguchi M, Okamura T, et al. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig, 2022, 13(2): 308-316.
[12] Quek J, Ng CH, Tang ASP, et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12620736 individuals. Endocr Pract, 2022, 28(7):667-672.
[13] Jung CY, Koh HB, Park KH, et al. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: a nationwide cohort study. Diabetes Metab, 2022, 48(4): 101344.
[14] Liang Y, Chen H, Liu Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab, 2022, 107(1):88-97.
[15] Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol, 2022, 18(4): 259-268.
[16] Li Y, Zhu B, Song N,et al. Alcohol consumption and its association with chronic kidney disease: evidence from a 12-year China health and nutrition survey. Nutr Metab Cardiovasc Dis, 2022, 32(6): 1392-1401.
[17] Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol, 2020, 72(4): 785-801.
[18] Matovani A, Zusi C, Sani E, et al. Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes Metab, 2019, 45(5): 480-487.
[19] Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfers of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem, 2018, 293(18): 6958-6968.
[20] Luukkonen PK, Tukiainen T, Juuti A, et al. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI insight, 2020, 5(5):e132158.
[21] Luukkonen PK, Zhou Y, Haridas PAN, et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. J Hepatol, 2017, 67(1): 128-136.
[22] Sliz E, Sebert S, Würtz P, et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum Mol Genet, 2018, 27(12): 2214-2223.
[23] Xia M, Zeng H, Wang S, et al. Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling. J Hepatol, 2021, 74(4): 974-977.
[24] Meijers B, Evenepoel P, Anders HJ. Intestinal microbiome and fitness in kidney disease. Nat Rev Nephrol, 2019, 15(9): 531-545.
[25] Tan X, Liu Y, Long J, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease. Mol Nutr Food Res, 2019, 63(17): 1900257.
[26] Wang XX, Luo Y, Wang D, et al. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. J Biol Chem, 2017, 292(29): 12018-12024.
[27] Herman-Edelstein M, Weinstein T, Levi M. Bile acid receptors and the kidney. Curr Opin Nephrol Hypertens, 2018, 27(1): 56-62.
[28] Wang S, Lv D, Jiang S, et al. Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease. Clin Sci (Lond), 2019, 133(17): 1857-1870.
[29] Zhao ZH, Wang ZX, Zhou D, et al. Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene. Cell Mol Gastroenterol Hepatol, 2021, 12(3): 857-871.
[30] Chambers ES, Morrison DJ, Frost G. Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms?. Proc Nutr Soc, 2015, 74(3): 328-336.
[31] Zhang S, Zhao J, Xie F, et al. Dietary fiber-derived short-chain fatty acids: a potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Rev, 2021, 22(11): e13316.
[32] Xu K, Zhao X, Fu X, et al. Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): a clinical analysis and mechanistic study. Biomed Pharmacother, 2019, 117: 109158.
[33] Ding R B, Bao J, Deng CX. Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci, 2017, 13(7): 852-867.
[34] Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med, 2013, 19(11): 1496-1504.
[35] Ralto KM, Rhee EP, Parikh SM. NAD+ homeostasis in renal health and disease. Nat Rev Nephrol, 2020, 16(2): 99-111.
[36] Tsaousidou E, Paeger L, Belgardt BF, et al. Distinct roles for JNK and IKK activation in agouti-related peptide neurons in the development of obesity and insulin resistance. Cell Rep, 2014, 9(4): 1495-1506.
[37] Shi Y, Fan J. Therapeutic developments in metabolic dysfunction-associated fatty liver disease. Chin Med J (Engl), 2022, 135(09): 1009-1018.
[38] Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. Metabolism, 2021, 115: 154433.
[39] 林苏. 非酒精性脂肪性肝病与慢性肾脏病. 福建医科大学, 2021.
[40] Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2017, 45(2): 332-344.